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IMPORTANCE Dual blockade of programmed death ligand 1 (PD-L1) and cytotoxic
T-lymphocyte associated protein 4 (CTLA-4) may overcome immune checkpoint inhibition. It
is unknown whether dual blockade can potentiate antitumor activity without compromising
safety in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M
HNSCC) and low or no PD-L1 tumor cell expression.
OBJECTIVE To assess safety and objective response rate of durvalumab combined with
tremelimumab.
DESIGN, SETTING, AND PARTICIPANTS The CONDOR study was a phase 2, randomized,
open-label study of Durvalumab, Tremelimumab, and Durvalumab in Combination With
Tremelimumab in Patients With R/M HNSCC. Eligibility criteria included PD-L1–low/negative
disease that had progressed after 1 platinum-containing regimen in the R/M setting. Patients
were randomized (N = 267) from April 15, 2015, to March 16, 2016, at 127 sites in North
America, Europe, and Asia Pacific.
INTERVENTIONS Durvalumab (20 mg/kg every 4 weeks) + tremelimumab (1 mg/kg every 4
weeks) for 4 cycles, followed by durvalumab (10 mg/kg every 2 weeks), or durvalumab (10
mg/kg every 2 weeks) monotherapy, or tremelimumab (10 mg/kg every 4 weeks for 7 doses
then every 12 weeks for 2 doses) monotherapy.
MAIN OUTCOMES AND MEASURES Safety and tolerability and efficacy measured by objective
response rate.
RESULTS Among the 267 patients (220 men [82.4%]), median age (range) of patients was
61.0 (23-82) years. Grade 3/4 treatment-related adverse events occurred in 21 patients
(15.8%) treated with durvalumab + tremelimumab, 8 (12.3%) treated with durvalumab, and 11
(16.9%) treated with tremelimumab. Grade 3/4 immune-mediated adverse events occurred
in 8 patients (6.0%) in the combination arm only. Objective response rate (95% CI) was 7.8%
(3.78%-13.79%) in the combination arm (n = 129), 9.2% (3.46%-19.02%) for durvalumab
monotherapy (n = 65), and 1.6% (0.04%-8.53%) for tremelimumab monotherapy (n = 63);
median overall survival (95% CI) for all patients treated was 7.6 (4.9-10.6), 6.0 (4.0-11.3), and
5.5 (3.9-7.0) months, respectively.
CONCLUSIONS AND RELEVANCE In patients with R/M HNSCC and low or no PD-L1 tumor cell
expression, all 3 regimens exhibited a manageable toxicity profile. Durvalumab and
durvalumab + tremelimumab resulted in clinical benefit, with minimal observed difference
between the two. A phase 3 study is under way.
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A pproximately 60% of patients with head and neck squa-mous cell carcinoma (HNSCC) present with locally ad-vanced or metastatic disease; survival rates are low and
many will experience relapse with locoregional recurrence,
and/or metastatic disease.1,2 Patients with disease progres-
sion after first-line combination chemotherapy with or with-
out biologic therapy have poor prognoses and are typically
treated with single agents (eg, methotrexate, docetaxel, or ce-
tuximab), which yield objective response rates (ORRs) of 4%
to 13%.3-6
Agents targeting the anti–programmed death 1 (PD-1)/
programmed death ligand 1 (PD-L1) pathway have shown
promising activity in recurrent/metastatic (R/M) HNSCC
with 2 PD-1 monoclonal antibodies (mAbs) approved for
treatment of patients with platinum-refractory R/M
HNSCC.7-10 Durvalumab, a human IgG1 mAb that blocks
PD-L1 binding to PD-1 and CD80, has also shown antitumor
activity as monotherapy in R/M HNSCC. In a phase 1/2 study
to evaluate durvalumab,11 an ORR of 11% was achieved with
durvalumab monotherapy; in the Phase II Study of Dur-
valumab Monotherapy in Treatment of Recurrent or Meta-
static Squamous Cell Carcinoma of the Head and Neck
(HAWK),12 durvalumab demonstrated an ORR of 16.2% with
a median duration of response of 10.3 months in patients
with 25% or more tumor cells expressing PD-L1 (TC≥25%)
whose disease progressed after 1 line of platinum-based
therapy in the R/M setting.11,12
Expression of PD-L1 has been shown to be predictive of
efficacy for PD-1/PD-L1 targeted therapy in several tumor
types, including HNSCC.13-16 The PD-L1 cutoff of TC25% was
derived from a phase 1/2 study of durvalumab mono-
therapy, in which response rates in R/M HNSCC were 18% in
patients with PD-L1 expression TC≥25% and 8% in patients
with PD-L1 expression TC<25%.16-18 Although there is a clear
difference in efficacy in these 2 groups, which supports the
use of the TC25% cutoff, durvalumab monotherapy did
show modest activity for patients with PD-L1 expression
TC<25%, which is consistent with other single-agent activ-
ity in patients with R/M HNSCC.
Dual-targeted immunotherapy is an approach that can im-
prove on the efficacy of monotherapy, and combining anti–
PD-L1 and anti–cytotoxic T-lymphocyte–associated protein
4 (CTLA-4) mAbs has shown enhanced preclinical and clini-
cal antitumor activity over either agent alone, indicating that
the 2 pathways are not redundant.7,19-21 The combination of
PD-1/PD-L1 and CTLA-4 targeting agents has demonstrated syn-
ergistic antitumor activity regardless of PD-L1 expression
levels.22 Furthermore, the combination of durvalumab and
tremelimumab, a selective human IgG2 anti–CTLA-4 mAb, has
specifically shown efficacy in patients with PD-L1–low/
negative tumors.15,23-25 Based on these and other data,26,27 ad-
dition of an anti–CTLA-4 mAb to enhance antitumor activity
of anti–PD-L1 agents in patients with R/M HNSCC and PD-L1–
low/negative tumors warrants investigation.
Herein we present results from the phase 2, random-
ized, open-label study of Durvalumab, Tremelimumab, and
Durvalumab in Combination With Tremelimumab in
Patients With R/M HNSCC (CONDOR) study. To our knowl-
edge, this is the first study to specifically focus on patients
with PD-L1–low/negative (TC <25%) R/M HNSCC with dis-
ease progression on or after a single platinum-containing
regimen in the R/M setting.
Methods
Patients
Patients were enrolled from April 15, 2015, to March 16,
2016, at 127 sites in 15 countries in North America, Europe,
and the Asia Pacific region. Eligible patients had disease
progression or recurrence during or after treatment with
only 1 platinum-containing regimen for R/M disease and
were 18 years or older with confirmed R/M HNSCC of the
oropharynx, oral cavity, hypopharynx, or larynx. Other key
eligibility criteria included provision of newly acquired (pre-
ferred) or archival tumor tissue (<3 years old) for PD-L1
expression, confirmed PD-L1–low/negative HNSCC
(TC<25%, using the validated VENTANA PD-L1 [SP263]
Assay [Ventana Medical Systems]), and Eastern Cooperative
Oncology Group performance status of 0 (normal activity)
or 1 (restricted activity) at enrollment. Key exclusion criteria
can be found in the eAppendix in Supplement 1. Review and
approval of the study and diagnostic testing by an institu-
tional review board or ethics committee was obtained for
each site. The full trial protocol is provided in Supplement
2. Written informed consent from participants and any addi-
tional locally required authorization was obtained before
performing any protocol-related procedures.
Study Design and Treatment
CONDOR was a randomized, open-label, multicenter, global
phase 2 study. Patients were stratified by human papilloma-
virus (HPV) status and smoking status and then randomized
2:1:1 to treatment with durvalumab + tremelimumab
Key Points
Question Does dual-target immuno-oncology therapy
(anti–programmed death ligand 1 [PD-L1] and anticytotoxic
T-lymphocyte associated protein 4) have clinically meaningful
antitumor activity without compromising safety in patients with
recurrent and/or metastatic head and neck squamous cell
carcinoma (R/M HNSCC) and low or no tumor cell expression of
PD-L1?
Findings In this phase 2 randomized clinical trial of 267 patients,
durvalumab monotherapy and durvalumab + tremelimumab
demonstrated manageable toxic effects and clinically relevant
overall survival for patients with R/M HNSCC and low or no PD-L1
tumor cell expression; durvalumab monotherapy and durvalumab
+ tremelimumab combination therapy showed similar efficacy.
Meaning Treatment with durvalumab monotherapy and
durvalumab + tremelimumab resulted in clinical benefit in patients
with PD-L1–low/negative tumor cell expression, but no significant
difference in efficacy or adverse effects was observed between
the 2 regimens.
Research Original Investigation Durvalumab Monotherapy and Combination Therapy in PD-L1–Low/Negative HNSCC
196 JAMA Oncology February 2019 Volume 5, Number 2 (Reprinted) jamaoncology.com
© 2018 American Medical Association. All rights reserved.
Downloaded From: https://jamanetwork.com/ on 10/26/2020
(20 mg/kg durvalumab every 4 weeks plus 1 mg/kg tremeli-
mumab every 4 weeks) for 4 cycles followed by durvalumab
(10 mg/kg every 2 weeks), durvalumab monotherapy
(10 mg/kg every 2 weeks) or tremelimumab monotherapy
(10 mg/kg every 4 weeks for 7 doses then every 12 weeks for
2 additional doses) for up to 12 months. All treatment was
administered via intravenous infusion. Computer software
programming generated and allocated blocked randomiza-
tion codes, which were assigned sequentially within each
stratum via an interactive voice–interactive web response
system. All study centers used the same list to minimize
treatment assignment imbalances. Treatment beyond pro-
gressive disease was permitted for up to 12 months if a
patient continued to receive benefit from the assigned treat-
ment, met criteria for treatment in the setting of progressive
disease, and, in the case of combination treatment, only if
progressive disease occurred during the monotherapy por-
tion. Human papillomavirus status was evaluated in all
patients regardless of tumor location either from medical
records (when available) or assessed in licensed clinical
laboratories per local standard procedures or central testing
(if local testing was not available).
Study Assessments
The primary objective was the ORR of durvalumab + treme-
limumab using blinded independent central review (BICR)
assessment according to Response Evaluation Criteria in
Solid Tumours Working Group (RECIST), version 1.1. Tumor
assessments were performed by using computed tomogra-
phy or magnetic resonance imaging every 8 weeks for the
first 48 weeks, then every 12 weeks in patients with disease
control after 12 months until confirmed progressive disease.
Secondary outcomes were the ORR in the monotherapy
arms, duration of response, best objective response, disease
control rate, progression-free survival, overall survival (OS),
and safety in all arms. Health-related quality of life was
assessed and will be reported elsewhere. Treatment-related
adverse events (TRAEs) were monitored and graded accord-
ing to the National Cancer Institute Common Terminology
Criteria for Adverse Events, version 4.03.28 Adverse events
of special interest were defined as events with potential
inflammatory or immune-mediated mechanisms that may
require more frequent monitoring or interventions, such as
steroid, immunosuppressant, or hormone therapy.
Immune-mediated adverse events (imAEs) were adverse
events of special interest considered to have immune-
mediated mechanisms of action.
Statistical Analysis
The study planned to screen 384 patients to identify and ran-
domize approximately 240 patients with PD-L1–low/negative
disease and to evaluate at least 208 patients for primary and
secondary end points. No formal statistical comparisons were
planned, although a sample size of 104 was deemed to pro-
vide greater than 90% power to test the hypothesis that the
ORR of greater than 13% assuming the true ORR was 27% in
the evaluable analysis set of patients treated with combina-
tion therapy. Descriptive statistics were used for all variables,
as appropriate, and were presented by treatment group. Effi-
cacy data were summarized and analyzed based on either the
evaluable analysis set (patients receiving assigned treatment
and with tumor assessment with measurable disease at base-
line according to BICR), full analysis set (patients random-
ized to treatment or “intention-to-treat” population), or both.
Kaplan-Meier plots and median values of progression-free sur-
vival and OS end points were determined and presented using
a 95% CI and 2-sided P value, unless otherwise stated. An ex-
ploratory analysis of ORR was performed for PD-L1 at cutoffs
of TC≥1% and TC≥10%. Safety data were summarized based on
the safety analysis set and for the first 12 months of treat-
ment only. Statistical analyses were performed using SAS soft-
ware (SAS Institute Inc).
Results
Patient Disposition and Baseline Characteristics
Data cutoff occurred March 31, 2017, approximately 12 months
after the last patient entered the study. Two hundred sixty-
seven patients were randomized: 133 to receive treatment with
durvalumab + tremelimumab, 67 to receive durvalumab mono-
therapy, and 67 to receive tremelimumab monotherapy
(Figure 1 and eTable in Supplement 1). A total of 257 patients
received the assigned treatment and had tumor assessment
with measurable disease at baseline according to BICR. Of
these, 136 patients (52.9%) had PD-L1 TC<1%, 77 (30.0%) had
PD-L1 TC≥1% but TC<10%, and 44 (17.1%) had PD-L1 TC≥10%
but TC<25%, with a similar distribution among treatment arms.
Overall, 212 patients (82.5%) had recurrence within 6 months
after the last dose of a platinum-containing regimen, and 198
(74.2%) received cetuximab before study enrollment. Pa-
tients received a median of 2 previous lines of therapy: 121
(45.3%) received 1, 134 (50.2%) received 2, and 11 (4.1%) pa-
tients received 3 previous lines of therapy. Previous therapy
included treatments with curative intent for locally ad-
vanced, neoadjuvant, adjuvant, and R/M disease or with con-
current chemotherapy (eg, chemoradiotherapy, radio-
therapy, and/or surgery).
Baseline characteristics were generally well balanced
among the 3 treatment arms and representative of a patient
population with platinum-refractory R/M HNSCC (Table 1).
One hundred seven tumors (40.1%) were located in the oro-
pharynx, whereas 60 patients (22.5%) had primary tumors
in the larynx, 54 (20.2%) in the oral cavity, and 43 (16.1%) in
the hypopharynx. Human papillomavirus status was evalu-
ated in all patients regardless of primary site: 75 (28.1%)
patients had HPV, including 39 (29.3%) in the combination
arm, 18 (26.9%) in the durvalumab arm, and 18 (26.9%) in
the tremelimumab arm.
Safety
Rates of TRAEs, but not of imAEs, were similar in the 3 arms
(Table 2). Treatment-related AEs of any grade were seen in
77 patients (57.9%) in the combination arm, 41 (63.1%) in the
durvalumab arm, and 36 (55.4%) in the tremelimumab arm.
Overall, the most common TRAEs of any grade were diarrhea
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(36 patients [13.7%]), fatigue (24 [9.1%]), and asthenia
(22 [8.4%]). Grade 3/4 TRAEs occurred in 21 patients (15.8%)
in the combination arm, 8 (12.3%) in the durvalumab arm, and
11 (16.9%) in the tremelimumab arm. Treatment-related imAEs
were reported in 26 patients (19.5%) in the combination arm
and 5 (7.7%) in the durvalumab arm, but none in the tremeli-
mumab arm. Grade 3/4 treatment-related imAEs were re-
ported in 8 patients (6.0%) in the combination arm only. These
adverse events were generally manageable, and were revers-
ible in many cases. Bleeding events included hemorrhage in
1 patient (0.8%) in the combination arm, epistaxis in 3 pa-
tients (4.6%) in the combination arm and 1 (1.5%) in the dur-
valumab arm, and hemoptysis in 5 patients (3.8%) in the com-
bination arm, 1 (1.5%) in the durvalumab arm, and 1 (1.5%) in
the tremelimumab arm. Two bleeding events in the combina-
tion arm were considered treatment related, including 1 pa-
tient each with epistaxis and hemoptysis. Overall, 12 patients
(4.6%) discontinued treatment owing to TRAEs. Common rea-
sons were diarrhea (6 reports), dehydration (2 reports), and
hepatobiliary disorders (2 reports). No patient from the dur-
valumab arm discontinued treatment owing to TRAEs.
One treatment-related death occurred. A 72-year-old
man in the combination arm experienced treatment-related
grade 3 acute respiratory failure 38 days after his first and
only administration of therapy and died 50 days after
administration. The primary cause of death was squamous
cell carcinoma disease progression.
Efficacy
A reduction in target lesion size from baseline was reported in
40 patients (31.0%) in the combination arm, 15 (23.1%) in the dur-
valumab arm, and 9 (14.3%) in the tremelimumab arm (eFigure
inSupplement1).Formostpatients,nonewlesionswerereported
during the study.
Objective response rate by BICR in patients treated with dur-
valumab + tremelimumab was 7.8% (95% CI, 3.78%-13.79%) and
was 9.2% (95% CI, 3.46%-19.02%) in the durvalumab arm and
1.6% (95% CI, 0.04%-8.53%) in the tremelimumab arm (Table 3);
all were partial responses. In patients who responded, the me-
dian time to response (range) was 2.0 (2-6) months in the com-
bination arm, 4.1 (2-6) months in the durvalumab arm, and
1.8 months (range not applicable; 1 patient responded) in the
tremelimumab arm. At data cutoff, responses were ongoing in
5 of 10 patients (50%) in the combination arm, 4 of 6 (66.7%) in
the durvalumab arm, and 1 of 1 (100%) in the tremelimumab arm.
The median (interquartile range) duration of response was 9.4
(4.9-not applicable) months in the combination arm and had not
been reached in the durvalumab or tremelimumab arms. The
ORR for patients with PD-L1–negative disease (TC<1%) was 7.4%
(5 of 68 patients) in the combination arm, and 8.8% (3 of 34) in
the durvalumab arm. The ORR for patients with TC<10% was
6.8% (7 of 103 patients) in the combination arm and 8.9% (5 of
56) in the durvalumab arm.
Among patients with HPV-positive tumors, the ORR was
5.4% (95% CI, 0.66%-18.19%) in the combination arm and 16.7%




67 Randomized to durvalumab
65 Received durvalumab
2 Did not receive durvalumab
67 Randomized to tremelimumab
65 Received tremelimumab
2 Did not receive tremelimumab
133 Randomized to durvalumab and
tremelimumab
133 Received durvalumab and
tremelimumab
67 Included in FAS
65 Included in EAS
2 Did not receive treatment
0 Did not have baseline tumor
assessment
0 Did not have measureable
disease at baseline according
to BICR
65 Included in SAS
2 Did not receive treatment
67 Included in FAS
63 Included in EAS
2 Did not receive treatment
1 Did not have baseline tumor
assessment
1 Did not have measurable
disease at baseline according
to BICR
65 Included in SAS
2 Did not receive treatment
133 Included in FAS
129 Included in EAS
0 Did not receive treatment
2 Did not have baseline tumor
assessment
2 Did not have measurable
disease at baseline according
to BICR
133 Included in SAS
0 Did not receive treatment



























All patients randomized are included
in the full analysis set (FAS).
EAS indicates evaluable analysis set;
SAS, safety analysis set.
a These patients did not meet all
inclusion criteria, including
programmed death ligand 1 low or
no tumor expression, or met at least
1 of the exclusion criteria.
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(95% CI, 3.58%-41.42%) in the durvalumab arm. However, the
95% CIs for this subgroup were wide; therefore, this result should
be interpreted with caution. The patient in the tremelimumab
arm with partial response was HPV negative.
Median (95% CI) progression-free survival was 2.0 (1.9-2.1)
months in the combination arm and 1.9 (1.8-2.8) months in the
durvalumab arm and 1.9 (1.8-2.0) months in the tremelim-
umab arm (Figure 2A). Risk of progression for patients receiv-
ing combination therapy vs durvalumab monotherapy (hazard
ratio [HR], 1.13; 95% CI, 0.82-1.56; P = .47) or tremelimumab
monotherapy (HR, 0.73; 95% CI, 0.53-1.01; P = .05) was not sta-
tistically significant. The 6-month progression-free survival rate
was higher in the combination arm (13.7%; 95% CI, 8.3%-
20.4%) and durvalumab arm (20.0%; 95% CI, 11.3%-30.4%) than
in the tremelimumab arm (1.9%; 95% CI, 0.2%-8.6%).
Median (range) follow-up was 6.5 (0.2-20.0) months in the
combination arm, 6.0 (0.3-18.0) months in the durvalumab arm,
and 5.2 (0.3-16.0) months in the tremelimumab arm. Median
(95% CI) OS were 7.6 (4.9-10.6) months in the combination arm,
6.0 (4.0-11.3) months in the durvalumab arm, and 5.5 (3.9-7.0)
months in the tremelimumab arm (Figure 2B). Risk of death for
patients receiving the combination vs durvalumab mono-
therapy (HR, 0.99; 95% CI, 0.69-1.43; P = .89) or tremelim-
umab monotherapy (HR, 0.72; 95% CI, 0.51-1.03; P = .06) was
not statistically significant. The OS rate at 12 months was 37%
in the combination arm, 36% in the durvalumab arm, and 24%
in the tremelimumab arm.
Discussion
To our knowledge, CONDOR was the first study to exclusively
focus on a population of patients with PD-L1–low/negative R/M
HNSCC in whom disease progressed on or after 1 platinum-
containing regimen in the R/M setting and the first to use an anti–
CTLA-4 mAb for patients with HNSCC. Durvalumab mono-
therapy in the CONDOR study showed an ORR of 9.2%. This
compares with an ORR of 14.6% for pembrolizumab vs 10.1%
for investigators’ choice of therapy in all comers in the Keynote-
040 study, and with an ORR of 13.3% for nivolumab vs 5.8% for
investigators’ choice in all comers in the CheckMate-141 trial.29,30
Studies to date of anti–PD-1 immuno-oncology agents indicate
that PD-L1 expression is associated with response rate. In the
single-arm Keynote-055 study, pembrolizumab ORR was 12%
in the subgroup with PD-L1 TC<1% vs 18% in the subgroup with
PD-L1 TC≥1%.31 Similarly, in the Checkmate-141 study, nivolumab
ORR was 12.3% vs 17% in the same subgroups. In contrast, in
our study, ORR within each treatment group, and PD-L1 sub-
group, was broadly similar irrespective of the PD-L1 expres-
sion grouping within patients with low or no expression of PD-












Age, median (range), y 62 (26-81) 62 (23-82) 61 (42-77) 61 (23-82)
Male, No. (%) 113 (85.0) 54 (80.6) 53 (79.1) 220 (82.4)
ECOG PS 1,b No. (%) 93 (69.9) 45 (67.2) 48 (71.6) 186 (69.7)
HPV positive,c No. (%) 39 (29.3) 18 (26.9) 18 (26.9) 75 (28.1)
Smoking/nicotine use, No (%)
Current/former 113 (85.0) 58 (86.6) 53 (79.1) 224 (83.9)
>10 Pack-years 81 (60.9) 42 (62.7) 40 (59.7) 163 (61.0)
≤10 Pack-years 32 (24.1) 16 (23.9) 13 (19.4) 61 (22.8)
Never 20 (15.0) 9 (13.4) 14 (20.9) 43 (16.1)
Previous therapy, No. (%)
Cetuximab 99 (74.4) 50 (74.6) 49 (73.1) 198 (74.2)
Taxane 59 (44.4) 26 (38.8) 26 (38.8) 111 (41.6)
Chemotherapy (other)d 97 (72.9) 49 (73.1) 51 (76.1) 197 (73.8)
Radiotherapy 117 (88.0) 58 (86.6) 62 (92.5) 237 (88.8)
≤6 mo From previous platinum
therapy, No. (%)
106 (82.8) 53 (82.8) 53 (81.5) 212 (82.5)
Overall disease classification, No. (%)
Locally advanced diseasee 50 (37.6) 22 (32.8) 24 (35.8) 96 (36.0)
Metastatic diseasef 83 (62.4) 45 (67.2) 43 (64.2) 171 (64.0)
Primary tumor location, No. (%)
Oropharynx 52 (39.1) 25 (37.3) 30 (44.8) 107 (40.1)
Oral cavity 24 (18.0) 15 (22.4) 15 (22.4) 54 (20.2)
Hypopharynx 25 (18.8) 8 (11.9) 10 (14.9) 43 (16.1)
Larynx 32 (24.1) 17 (25.4) 11 (16.4) 60 (22.5)
Otherg 0 2 (3.0) 1 (1.5) 3 (1.1)
Abbreviations: ECOG, Eastern
Cooperative Oncology Group;
FAS, full analysis set; HPV, human
papillomavirus; PS, performance
status.
a Percentages are based on the
number of patients with data for
each baseline characteristic.
b ECOG PS 1 indicates restricted
activity.
c Human papillomavirus status was
evaluated in all patients.
d All other chemotherapy and
chemotherapy regimens, with the
exception of platinum agents and
taxanes.
e Patients with recurrent disease.
f Patients with metastatic disease at
any site.
g Other tumor locations include neck
spinocellular carcinoma–larynx,
lymph nodes from right
submandibular area, and
synchronous both oropharynx and
hypopharynx.
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L1. In the HAWK study, which enrolled only patients with PD-
L1–high expression (TC≥25%), durvalumab ORR was 16.2%.12
Although cross-trial comparisons can be challenging, study
populations among the Keynote-040, CheckMate-141, and
CONDOR trials had several similarities. All studies enrolled pa-
tients with R/M HNSCC and disease progression after platinum-
containing chemotherapy; Keynote-040 enrolled patients
within 3 to 6 months of multimodal platinum-based therapy,












All-grade TRAEs, No. (%)a 77 (57.9) 41 (63.1) 36 (55.4) 154 (58.6)
Diarrhea 19 (14.3) 7 (10.8) 10 (15.4) 36 (13.7)
Asthenia 13 (9.8) 5 (7.7) 4 (6.2) 22 (8.4)
Hypothyroidism 11 (8.3) 7 (10.8) 1 (1.5) 19 (7.2)
Decreased appetite 11 (8.3) 2 (3.1) 3 (4.6) 16 (6.1)
Rash 9 (6.8) 1 (1.5) 5 (7.7) 15 (5.7)
Fatigue 8 (6.0) 12 (18.5) 4 (6.2) 24 (9.1)
Anemia 8 (6.0) 1 (1.5) 0 9 (3.4)
Nausea 7 (5.3) 1 (1.5) 5 (7.7) 13 (4.9)
Pyrexia 6 (4.5) 0 4 (6.2) 10 (3.8)
Pruritus 5 (3.8) 5 (7.7) 3 (4.6) 13 (4.9)
Vomiting 2 (1.5) 1 (1.5) 5 (7.7) 8 (3.0)
Grade 3/4 TRAEs, No. (%)b 21 (15.8) 8 (12.3) 11 (16.9) 40 (15.2)
Diarrhea 4 (3.0) 0 3 (4.6) 7 (2.7)
Anemia 3 (2.3) 0 0 3 (1.1)
Asthenia 3 (2.3) 0 0 3 (1.1)
Fatigue 1 (0.8) 2 (3.1) 1 (1.5) 4 (1.5)
Treatment-related SAE, No. (%) 17 (12.8) 1 (1.5) 8 (12.3) 26 (9.9)
Treatment-related AESI, No. (%) 47 (35.3) 23 (35.4) 20 (30.8) 90 (34.2)
Treatment-related imAE, No. (%) 26 (19.5) 5 (7.7) 0 (0.0) 31 (11.8)
Grade 3/4 treatment-related imAE,
No. (%)
8 (6.0) 0 (0.0) 0 (0.0) 8 (3.0)
TRAE leading to dose interruption, No. (%) 11 (8.3) 4 (6.2) 6 (9.2) 21 (8.0)
TRAE leading to dose discontinuation,
No. (%)
7 (5.3) 0 5 (7.7) 12 (4.6)
TRAE leading to death, No. (%) 1 (0.8)c 0 0 1 (0.4)
Abbreviations: AESI, adverse event of
special interest;
imAE, immune-mediated adverse
event; SAE, serious adverse event;
SAS, safety analysis set; TRAEs,
treatment-related adverse events.
a Individual adverse events with
incidence greater than 5% in any
arm are reported.
b Individual grade 3/4 adverse events
with incidence greater than 2% in
any arm are reported.
c Grade 3 acute respiratory failure.







(n = 129) Durvalumab (n = 65) Tremelimumab (n = 63)
ORR, No. (%) [95% CI]a 10 (7.8) [3.78-13.79] 6 (9.2) [3.46-19.02] 1 (1.6) [0.04-8.53] 17 (6.6)
Odds ratio (95% CI)b 1 [Reference] 0.83 (0.29-2.53) 5.21 (0.96-96.70) NA
P value .73 .06
Complete response,
No.
0 0 0 0
Partial response,
No. (%)
10 (7.8) 6 (9.2) 1 (1.6) 17 (6.6)
Stable disease ≥6 mo,
No. (%)
7 (5.4) 4 (6.2) 0 11 (4.3)
Progressive disease,
No. (%)
83 (64.3) 42 (64.6) 44 (69.8) 169 (65.8)
DCR at 6 mo, No. (%)c 17 (13.2) 14 (21.5) 1 (1.6) 32 (12.5)
Median (range) time to
response, mo
2.0 (2-6) 4.1 (2-6) 1.8 (NA) 3.5 (2-6)
Median (IQR) duration of
response, mo
9.4 (4.9-NA) NA NA NA
Ongoing response at data
cutoff, No. (%)
5 (50.0) 4 (66.7) 1 (100) 10 (58.8)
Abbreviations: DCR, disease control
rate; IQR, interquartile range; NA, not
applicable; ORR, objective response
rate.
a ORR at 12 months of treatment
based on blinded independent
central review assessments using
RECIST, version 1.1.
b Odds ratio is a comparison between
groups (combination vs
monotherapy); an odds ratio greater
than 1 favors the combination.
c Patients who had a best objective
response of complete response or
partial response in the first 24
weeks or demonstrated stable
disease for a minimum interval of
24 weeks following randomization.
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and CheckMate-141 enrolled patients within 6 months after plati-
num-containing chemotherapy.32,33 More than 80% of
patients in the CONDOR study had disease recurrence within
6 months of the last dose of a platinum-containing regimen.
CONDOR, CheckMate-141, and Keynote-040 included similar
percentages of HPV-positive patients (28.1%, 25.6%, and 24.0%,
respectively).32,33 In addition, 74.2% of patients had previ-
ously received cetuximab in CONDOR, and 61.3% had previ-
ously received cetuximab in CheckMate-141.33 Keynote-040 and
CheckMate-141 did enroll all comers in terms of PD-L1 expres-
sion; therefore, some patients had high PD-L1 expression ac-
cording to the specific algorithms used for those studies.
The CONDOR study was not powered to compare the com-
bination and monotherapy arms, but addition of tremeli-
mumab did not appear to improve outcomes compared with
single-agent durvalumab in patients with PD-L1–low/negative
disease. However, both the combination and durvalumab mono-
therapy arms showed clinically relevant OS. In Keynote-040,
median OS was 8.4 months for pembrolizumab vs 6.9 months
for investigators’ choice of therapy, whereas, in patients with a
combined positive score of 1 or higher (PD-L1 TC and immune
cell expression ≥1), median OS was 8.7 months with pembroli-
zumab vs 7.1 months with investigators’ choice of therapy. In
patients with a tumor proportion score of greater than 50%, me-
dian OS was 11.6 months with pembrolizumab vs 6.6 months
with investigators’ choice of therapy.32 In CheckMate-141, me-
dian OS in response to nivolumab treatment was 8.2 months for
patients with PD-L1–positive expression (≥1% tumor cell mem-
brane staining) vs 6.5 months for patients with PD-L1–negative
expression (<1% tumor cell membrane staining).33 Consider-
ing all comers in CheckMate-141, in which the median OS in re-
sponse to nivolumab therapy was 7.7 months vs 5.1 months for
the investigators’ choice of therapy, our study shows similar me-
dian survival for patients treated with durvalumab + tremeli-
mumab (7.6 months) or durvalumab alone (6.0 months), indi-
cating their potential utility irrespective of PD-L1 expression.
The rationale for combining anti–PD-L1 and anti–CTLA-4
mAbs has precedence in other tumor types, including PD-L1–low/
negative tumors. The combination of nivolumab and ipilimumab
has yielded higher ORRs compared with each monotherapy in
melanoma.34 A dose of 20 mg/kg of durvalumab plus 1 mg/kg of
tremelimumab was identified as the maximum tolerated dose
for this combination in a phase 1b study in patients with non–
small cell lung cancer, which demonstrated antitumor activity
in patients with PD-L1–low/negative (TC<25%) expression.15
Higher dosages of tremelimumab were evaluated in this early-
phase study but resulted in a higher frequency of TRAEs, grade
3 or 4 adverse events, and serious adverse events, without any
increaseinefficacy(ORR).15 Serumconcentrationlevelsoftreme-
limumab in combination with durvalumab did not show any
marked difference between doses and T-cell proliferation, and
activation markers for different doses of tremelimumab also did
not show any marked difference in this study.15 It is therefore un-
likely that the tremelimumab dose used in the combination arm
in the present study limited treatment efficacy. The lack of ef-
ficacy of tremelimumab may be related to its mechanism of ac-
tion, which as an IgG2 mAb does not cause lysis of regulatory T
cells through antibody-dependent cell-mediated cytotoxicity,
which is observed with ipilimumab.35 The clinical relevance of
this difference remains uncertain.
All arms exhibited manageable safety profiles in a patient
population with few treatment options. The durvalumab mono-
therapy safety profile is consistent with previous data,11,12 and
the combination arm produced no additional safety concerns.
Grade 3 or 4 TRAEs occurred in 15% of patients overall and imAEs
reported in the study were typical of the PD-1/PD-L1/CTLA-4
class of immunotherapies, which have previously been associ-
ated with hypothyroidism, diarrhea, pneumonitis, and





























































































































1.13 (0.82-1.56); P = .47




















0.99 (0.69-1.43); P = .89
0.72 (0.51-1.03); P = .06
HR (95% CI)a;
P Value
Hatching on plots indicates censored data.
a Stratified log rank test.
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colitis.11,12,15,26,27,30,31,36,37 One treatment-related death was re-
ported in a patient receiving combination therapy.
Limitations
The most apparent limitation to this study is that the study was
not powered to compare the combination and monotherapy
arms.
Conclusions
Durvalumab monotherapy showed a manageable toxicity pro-
file and clinical benefit for patients with R/M HNSCC and low
or no PD-L1 TC expression; durvalumab + tremelimumab dem-
onstrated similar efficacy to durvalumab monotherapy. Al-
though the CONDOR study was not powered to compare the
combination and monotherapy arms, our findings in this par-
ticular study do not appear to support the hypothesis that
tremelimumab combined with durvalumab exerts a synergis-
tic therapeutic effect in this population with low or no expres-
sion of PD-L1. CONDOR is part of a broader comprehensive clini-
cal program in HNSCC that includes patients with both PD-L1–
high and PD-L1–low/negative disease. The CONDOR study is
the first, to our knowledge, to focus on the use of an anti–PD-
L1/CTLA-4 combination and its respective monotherapies in
patients with PD-L1–low/negative disease. Continued efforts
are needed to improve outcomes in this challenging patient
population, perhaps in combination with additional or other
therapeutics that can stimulate the immune system without
adding significant toxicity. Further understanding of the
immune landscape of this group of tumors is germane to de-
signing rational combinations. The ongoing phase 3 study of
Durvalumab Monotherapy and in Combination With Tremeli-
mumab vs Standard of Care Therapy in Patients With Head and
Neck Cancer (EAGLE) will assess the combination of dur-
valumab + tremelimumab as second-line treatment in pa-
tients with PD-L1–high (TC≥25%) and PD-L1–low/negative
(TC<25%) R/M HNSCC.30
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